Avanza Fonder’s Alnylam Pharmaceuticals ALNY Stock Holding History

Avanza Fonder’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$120K	Hold	399	–	–	﹤0.01%	425
2026 Q1	$132K	Buy	+399	New	+$136K	﹤0.01%	434

Other funds holding ALNY

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Asset Management One Tokyo, Japan $39B AUM 37.51% 1-Year Est. Return

MIF

Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return

SSA

Sierra Summit Advisors Incline Village, Nevada $895M AUM 106% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Avanza Fonder's ALNY Position: Q2 2026 in Review

Avanza Fonder held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 399 shares worth $120K. The position accounts for ﹤0.01% of the portfolio, ranked #425.

Avanza Fonder first reported a position in ALNY in Q1 2026 and has held it in 2 quarters since. The position peaked at $132K in Q1 2026. 191 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Avanza Fonder held 399 shares of Alnylam Pharmaceuticals worth $120K as of Q2 2026.
Avanza Fonder left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
Alnylam Pharmaceuticals made up ﹤0.01% of Avanza Fonder's portfolio in Q2 2026, its #425 holding.
Avanza Fonder first reported a position in Alnylam Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
Avanza Fonder's Alnylam Pharmaceuticals position peaked at $132K in Q1 2026.
191 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Avanza Fonder's 13F filing for Q2 2026, filed 17 Jul 2026.